Testing of embryonic stem cell therapies in clinical trials might start in less than a year, possibly beginning with a study by pioneering researcher Hwang Woo-suk of Korea using the treatment for patients with spinal cord injuries. However, Hwang said tests involving embryonic stem cells instead of adult stem cells, which he thinks could trigger immunosupression in the patient, might take longer because the team of scientists must take "a conservative approach to ensure this is done properly for the good of human life."

Related Summaries